Intelligence Feed event · Macro · 2026-10-01

    Survodutide Phase III Trial Meets Endpoints with Up to 13.1% Weight Loss in T2D Obesity

    Question

    Survodutide Phase III Trial Meets Endpoints with Up to 13.1% Weight Loss in T2D Obesity

    Direct answer

    Topline results from the Phase III SYNCHRONIZE-2 clinical trial showed that survodutide produced mean weight reductions of up to 13.1% over 76 weeks compared to 3.1% for placebo among participants living with obesity and type 2 diabetes. The study also met secondary endpoints assessing glycemic control metrics. As a dual agonist of glucagon and GLP-1 receptors developed jointly by Boehringer Ingelheim and Zealand Pharma, the successful readout advances the candidate toward global regulatory submissions, adding competitive supply into the high-demand metabolic treatment category.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-01
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Survodutide Phase III Trial Meets Endpoints with Up to 13.1% Weight Loss in T2D Obesity”, revision 1, evidence through 2026-10-01. https://marketontology.com/market-events/2026-10-01/survodutide-phase-iii-trial-meets-endpoints-with-up-to-13-1-weight-loss-in-t2d-o-c6a77a

    MACRO
    Survodutide Phase III Trial Meets Endpoints with Up to 13.1% Weight Loss in T2D Obesity
    Topline results from the Phase III SYNCHRONIZE-2 clinical trial showed that survodutide produced mean weight reductions of up to 13.1% over 76 weeks compared to 3.1% for placebo among participants living with obesity and type 2 diabetes. The study also met secondary endpoints assessing glycemic control metrics. As a dual agonist of glucagon and GLP-1 receptors developed jointly by Boehringer Ingelheim and Zealand Pharma, the successful readout advances the candidate toward global regulatory submissions, adding competitive supply into the high-demand metabolic treatment category.
    ZLDPY
    Impact
    77
    OCT 1
    SIG
    92%
    ZLDPY
    Survodutide Phase III Trial Meets Endpoints with Up to 13.1% Weight Loss in T2D Obesity
    Topline results from the Phase III SYNCHRONIZE-2 clinical trial showed that survodutide produced mean weight reductions of up to 13.1% over 76 weeks compared to 3.1% for placebo among participants living with obesity and type 2 diabetes. The study also met secondary endpoints assessing glycemic control metrics. As a dual agonist of glucagon and GLP-1 receptors developed jointly by Boehringer Ingelheim and Zealand Pharma, the successful readout advances the candidate toward global regulatory submissions, adding competitive supply into the high-demand metabolic treatment category.
    → Statistically significant Phase III dual-agonist weight loss efficacy establishes a validated late-stage competitor in the metabolic therapeutic class, driving revenue re-evaluations for co-development partners.
    Impact
    Topline results from the Phase III SYNCHRONIZE-2 clinical trial showed that survodutide produced mean weight reductions of up to 13.1% over 76 weeks compared to 3.1% for placebo among participants living with obesity and type 2 diabetes. The study also met secondary endpoints assessing glycemic control metrics. As a dual agonist of glucagon and GLP-1 receptors developed jointly by Boehringer Ingelheim and Zealand Pharma, the successful readout advances the candidate toward global regulatory submissions, adding competitive supply into the high-demand metabolic treatment category.
    Affected
    ZLDPY
    Transmission
    Statistically significant Phase III dual-agonist weight loss efficacy establishes a validated late-stage competitor in the metabolic therapeutic class, driving revenue re-evaluations for co-development partners.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    ZLDPYmilestone validation and royalty pipeline revaluationUp1-4wZealand Pharma co-invented survodutide and is eligible for development milestones and commercial royalties.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month